295 related articles for article (PubMed ID: 31267805)
21. Efficacy and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in kidney transplant recipients.
Tojimbara T; Nakajima I; Yashima J; Fuchinoue S; Teraoka S
Transplant Proc; 2014; 46(2):511-3. PubMed ID: 24656001
[TBL] [Abstract][Full Text] [Related]
22. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
23. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
Tsuji T; Ohishi K; Takeda A; Goto D; Sato T; Ohashi N; Fujigaki Y; Kato A; Yasuda H
Clin Exp Nephrol; 2018 Dec; 22(6):1300-1308. PubMed ID: 29700702
[TBL] [Abstract][Full Text] [Related]
24. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M
J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025
[TBL] [Abstract][Full Text] [Related]
25. Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.
Sakai Y; Otsuka T; Ohno D; Murasawa T; Sato N; Tsuruoka S
Ren Fail; 2014 Mar; 36(2):225-31. PubMed ID: 24152124
[TBL] [Abstract][Full Text] [Related]
26. Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy.
Koide H; Hira D; Tsujimoto M; Katsube Y; Minegaki T; Uzu T; Ikeda Y; Morita SY; Nishiguchi K; Terada T
Biol Pharm Bull; 2017; 40(5):681-686. PubMed ID: 28458354
[TBL] [Abstract][Full Text] [Related]
27. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial).
Sezai A; Soma M; Nakata K; Hata M; Yoshitake I; Wakui S; Hata H; Shiono M
Circ J; 2013; 77(8):2043-9. PubMed ID: 23676888
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of febuxostat for treatment of asymptomatic hyperuricemia among kidney transplant patients: A meta-analysis of observational studies.
Chewcharat A; Chang YT; Thongprayoon C; Crisafio A; Bathini T; Mao MA; Cheungpasitporn W
Clin Transplant; 2020 Apr; 34(4):e13820. PubMed ID: 32034944
[TBL] [Abstract][Full Text] [Related]
29. Febuxostat for the chronic management of hyperuricemia in patients with gout.
Chinchilla SP; Urionaguena I; Perez-Ruiz F
Expert Rev Clin Pharmacol; 2016; 9(5):665-73. PubMed ID: 26942273
[TBL] [Abstract][Full Text] [Related]
30. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
[TBL] [Abstract][Full Text] [Related]
31. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
Sezai A; Unosawa S; Taoka M; Osaka S; Sekino H; Tanaka M
Ann Thorac Cardiovasc Surg; 2020 Aug; 26(4):202-208. PubMed ID: 31748427
[TBL] [Abstract][Full Text] [Related]
32. Effects of Febuxostat on Oxidative Stress.
Fukui T; Maruyama M; Yamauchi K; Yoshitaka S; Yasuda T; Abe Y
Clin Ther; 2015 Jul; 37(7):1396-401. PubMed ID: 25913922
[TBL] [Abstract][Full Text] [Related]
33. Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.
Stack AG; Han D; Goldwater R; Johansson S; Dronamraju N; Oscarsson J; Johnsson E; Parkinson J; Erlandsson F
J Clin Endocrinol Metab; 2021 Apr; 106(5):e2347-e2356. PubMed ID: 33075806
[TBL] [Abstract][Full Text] [Related]
34. Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD.
Sarvepalli PS; Fatima M; Quadri AK; Taher AR; Habeeb A; Amreen F; Parveen BN; Rajaram KG
Saudi J Kidney Dis Transpl; 2018; 29(5):1050-1056. PubMed ID: 30381500
[TBL] [Abstract][Full Text] [Related]
35. Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease.
Peng YL; Tain YL; Lee CT; Yang YH; Huang YB; Wen YH; Hsu CN
Sci Rep; 2020 Jul; 10(1):10734. PubMed ID: 32612180
[TBL] [Abstract][Full Text] [Related]
36. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout.
Faruque LI; Ehteshami-Afshar A; Wiebe N; Tjosvold L; Homik J; Tonelli M
Semin Arthritis Rheum; 2013 Dec; 43(3):367-75. PubMed ID: 24326033
[TBL] [Abstract][Full Text] [Related]
37. The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis.
Barrientos-Regala M; Macabeo RA; Ramirez-Ragasa R; Pestaño NS; Punzalan FER; Tumanan-Mendoza B; Castillo RR
J Cardiovasc Pharmacol; 2020 Oct; 76(4):461-471. PubMed ID: 32675751
[TBL] [Abstract][Full Text] [Related]
38. Hyperuricemia and Acute Renal Failure in Renal Transplant Recipients Treated With High-Dose Mizoribine.
Akioka K; Ishikawa T; Osaka M; Kadotani Y; Okugawa K; Nakano K; Osaka Y; Tsuchiya K; Sako H
Transplant Proc; 2017; 49(1):73-77. PubMed ID: 28104163
[TBL] [Abstract][Full Text] [Related]
39. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
40. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
